Subscribe
time_istock-183058651
daneger / iStockphoto.com
26 October 2018Americas

FDA improves generic approval rate under Trump: report

The US Food and Drug Administration’s (FDA) generic drug approval rate has increased at a “rapid rate” since January 2017, despite the number of branded drug patent expirations declining during this period.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
FDA’s Gottlieb launches biosimilars action plan
19 July 2018   The US Food and Drug Administration is not going to play regulatory ‘whack-a-mole’ with companies trying to delay or derail the entry of biosimilar competitors, according to Scott Gottlieb, commissioner of the FDA.
Americas
FDA issues guidance on generic versions of complex drugs
11 October 2018   The US Food and Drug Administration has released guidance intended to advance the development of generic versions of complex medical drugs.


Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024

Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024
Americas
Amarin wins appeal to advance ‘skinny label’ suit over Hikma generic
27 June 2024
Biotechnology
Guardant Health files suit against Tempus AI
13 June 2024
Big Pharma
Roche fires lawsuit at Sinocare unit over blood glucose test strip patents
6 June 2024

More on this story

Americas
FDA’s Gottlieb launches biosimilars action plan
19 July 2018   The US Food and Drug Administration is not going to play regulatory ‘whack-a-mole’ with companies trying to delay or derail the entry of biosimilar competitors, according to Scott Gottlieb, commissioner of the FDA.
Americas
FDA issues guidance on generic versions of complex drugs
11 October 2018   The US Food and Drug Administration has released guidance intended to advance the development of generic versions of complex medical drugs.

More on this story

Americas
FDA’s Gottlieb launches biosimilars action plan
19 July 2018   The US Food and Drug Administration is not going to play regulatory ‘whack-a-mole’ with companies trying to delay or derail the entry of biosimilar competitors, according to Scott Gottlieb, commissioner of the FDA.
Americas
FDA issues guidance on generic versions of complex drugs
11 October 2018   The US Food and Drug Administration has released guidance intended to advance the development of generic versions of complex medical drugs.

More features

Chinese biotech takes out US rival’s nucleic acid patent at PTAB
Lewis Roca promotes tech expert to managing partner
Panitch Schwarze brings in molecular biologist
US targets ‘product hopping’ with biologic litigation curbs
UPC confirms validity of Edwards Lifesciences heart valve tech patent
ITC concludes row over biotech lab equipment between US and German rivals
UKIPO launches ‘revolutionary’ patent filing and AI tool
USPTO clarifies AI's role in patent eligibility